Abstract:Abstract Background N6-methyladenosine (m6A) modification and long non-coding RNAs (lncRNAs) play pivotal roles in gastric cancer (GC) progression. The emergence of immunotherapy in GC has created a paradigm shift in the approaches of treatment, whereas there is significant heterogeneity with regard to degree of treatment responses, which results from the variability of tumor immune microenvironment (TIME). How the interplay between m6A and lncRNAs enrolling in the shaping of TIME remains unclear. Methods The RNA sequencing and clinical data of GC patients were collected from TCGA database. Pearson correlation test and univariate Cox analysis were used to screen out m6A-related lncRNAs. Consensus clustering method was implemented to classify GC patients into two clusters. Survival analysis, the infiltration level of immune cells, Gene set enrichment analysis (GSEA) and the mutation profiles were analyzed and compared between two clusters. A competing endogenous RNA (ceRNA) network and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were applied for the identification of pathways in which m6A-related lncRNAs enriched. Then least absolute shrinkage and selection operator (LASSO) COX regression was implemented to select pivotal lncRNAs, and risk model was constructed accordingly. The prognosis value of the risk model was explored. In addition, the response to immune checkpoint inhibitors (ICIs) therapy were compared between different risk groups. Finally, we performed qRT-PCR to detect expression patterns of the selected lncRNAs in the 35 tumor tissues and their paired adjacent normal tissues, and validated the prognostic value of risk model in our cohort ( N = 35). Results The expression profiles of 15 lncRNAs were included to cluster patients into 2 subtypes. Cluster1 with worse prognosis harbored higher immune score, stromal score, ESTIMATE score and lower mutation rates of the genes. Different immune cell infiltration patterns were also displayed between the two clusters. GSEA showed that cluster1 preferentially enriched in tumor hallmarks and tumor-related biological pathways. KEGG pathway analysis found that the target mRNAs which m6A-related lncRNAs regulated by sponging miRNAs mainly enriched in vascular smooth muscle contraction, cAMP signaling pathway and cGMP-PKG signaling pathway. Next, eight lncRNAs were selected by LASSO regression algorithm to construct risk model. Patients in the high-risk group had poor prognoses, which were consistent in our cohort. As for predicting responses to ICIs therapy, patients from high-risk group were found to have lower tumor mutation burden (TMB) scores and account for large proportion in the Microsatellite Instability-Low (MSI-L) subtype. Moreover, patients had distinct immunophenoscores in different risk groups. Conclusion Our study revealed that the interplay between m6A modification and lncRNAs might have critical role in predicting GC prognosis, sculpting TIME landscape and predicting the responses to ICIs therapy.

Analysis of N6-methyladenosine-related Lncrnas in the Tumor Immune Microenvironment and Their Prognostic Role in Pancreatic Cancer

Prognostic Risk Model and Tumor Immune Environment Modulation of M5c-Related LncRNAs in Pancreatic Ductal Adenocarcinoma

Significance of m 6A Methyltransferase‑Related lncRNAs in the Prognosis and Immunotherapy of Hepatocellular Carcinoma

Identification of N6-Methyladenosine-Associated Long Non-coding RNAs for Immunotherapeutic Response and Prognosis in Patients With Pancreatic Cancer

Characterization of the m6A-related lncRNA signature in predicting prognosis and immune response in patients with colon cancer

Identification of m6A/m5C/m1A-associated LncRNAs for prognostic assessment and immunotherapy in pancreatic cancer

Role of N6-methyladenosine Regulated Lncrnas in Prognosis, Tumor Microenvironment and Immune Checkpoints of Pancreatic Ductal Adenocarcinoma

A N6-methyladenosine-related Long Noncoding RNA is a Potential Biomarker for Predicting Pancreatic Cancer Prognosis

Aerial View of the Association Between m6A-Related LncRNAs and Clinicopathological Characteristics of Pancreatic Cancer

Signature of m5C-Related lncRNA for Prognostic Prediction and Immune Responses in Pancreatic Cancer

Prognostic Value of Drug Targets Predicted Using Deep Bioinformatic Analysis of m6A-Associated lncRNA-Based Pancreatic Cancer Model Characteristics and Its Tumour Microenvironment

Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer

Identification of m7G-Related LncRNA Signature for Predicting Prognosis and Evaluating Tumor Immune Infiltration in Pancreatic Adenocarcinoma

N6-Methylandenosine-Related Lncrna Signature is a Novel Biomarkers of Prognosis and Immune Response in Colon Adenocarcinoma Patients

A N6-methyladenosine-related Long Noncoding RNAs Model for Predicting Prognosis in Oral Squamous Cell Carcinoma: Association with Immune Cell Infiltration and Tumor Metastasis.

Identification of m6A-related lncRNAs as prognostic signature within colon tumor immune microenvironment

The Role of N6-Methyladenosine-Associated Lncrnas in the Immune Microenvironment and Prognosis of Colorectal Cancer

Comprehensive Analysis of Immune Cell Infiltration of M6a-Related Lncrna in Lung Squamous Cell Carcinoma and Construction of Relevant Prognostic Models

Comprehensive Analysis and Prognosis Prediction of N6-Methyladenosine-Related Lncrnas in Immune Microenvironment Infiltration of Gastric Cancer

Comprehensive Analysis of the Immune-Oncology Targets and Immune Infiltrates of N6-Methyladenosine-Related Long Noncoding RNA Regulators in Breast Cancer

Integrated analysis on the N6‐methyladenosine‐related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma